{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:09:08Z","timestamp":1787065748135,"version":"build-2736575974"},"reference-count":50,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T00:00:00Z","timestamp":1776556800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T00:00:00Z","timestamp":1776556800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Gain\/amplification of chromosome arm 1q (+1q) is among the most frequent cytogenetic abnormalities (CAs) in multiple myeloma (MM), and a recognized marker of poor prognosis, now integrated into modern risk stratification systems. The advent of anti\u2010CD38 monoclonal antibodies, particularly daratumumab, has significantly improved outcomes. However, the prognostic impact of +1q under daratumumab\u2010based treatments (DBTs) remains uncertain, since pivotal trials rarely reported +1q\u2010specific outcomes, and available real\u2010world data are limited and inconsistent. We conducted a single\u2010center retrospective study of 174\u2009MM patients treated with DBTs between 2018 and 2023 to evaluate the prognostic effect of +1q. By FISH cytogenetic assessment we identified standard\u2010risk (SR), isolated +1q, +1q plus additional high\u2010risk CAs (+1q\u2009+\u2009HiRCAs), and non\u20101q HiRCAs groups. The primary endpoint was progression\u2010free survival (PFS); secondary endpoints were time to next treatment (TTNT) and overall survival (OS). Median age was 72.0\u2009years, median line of DBT administration was 2, and 125 patients (71.8%) received daratumumab\u2010lenalidomide\u2010dexamethasone (DaraRd). Cytogenetic data were available for 92 patients (52.9%): 43 SR, 11 non\u20101q HiRCAs, 18 isolated +1q and 20 +1q\u2009+\u2009HiRCAs. After a median follow\u2010up of 30.7\u2009months, isolated +1q was associated with significantly shorter PFS (HR 4.77, 95% CI: 1.68\u201313.53) and TTNT (HR 3.83, 95% CI: 1.33\u201311.09) versus SR, while +1q\u2009+\u2009HiRCAs had the worst outcomes across all endpoints (PFS HR 7.67; TTNT HR 5.81; OS HR 6.03). Multivariate analysis confirmed isolated +1q as an independent predictor of inferior PFS (HR 4.56, 95% CI: 1.61\u201312.95) and TTNT (HR 3.64, 95% CI: 1.26\u201310.55), with +1q\u2009+\u2009HiRCAs conferring the highest risks on all outcomes (PFS HR 8.36; TTNT HR 6.37; OS HR 6.18). Findings were consistent in the DaraRd subgroup. These findings demonstrate that +1q retains prognostic significance in the era of DBTs. Isolated +1q remains an independent factor of adverse prognosis, further worsened by co\u2010existing HiRCAs.<\/jats:p>","DOI":"10.1111\/ejh.70198","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T04:12:47Z","timestamp":1776658367000},"page":"409-421","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prognostic Impact of Chromosome 1q Gain\/Amplification in Multiple Myeloma Treated With Daratumumab\u2010Based Regimens"],"prefix":"10.1111","volume":"117","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3148-6608","authenticated-orcid":false,"given":"Emiliano","family":"Barbieri","sequence":"first","affiliation":[{"name":"Hematology Unit, Azienda USL\u2010IRCCS di Reggio Emilia  Reggio Emilia Italy"},{"name":"Clinical and Experimental Medicine PhD Program University of Modena and Reggio Emilia  Modena Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Arletti","sequence":"additional","affiliation":[{"name":"Hematology Unit, Azienda USL\u2010IRCCS di Reggio Emilia  Reggio Emilia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micol","family":"Quaresima","sequence":"additional","affiliation":[{"name":"Hematology Unit, Azienda USL\u2010IRCCS di Reggio Emilia  Reggio Emilia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Rivolti","sequence":"additional","affiliation":[{"name":"Hematology Unit, Azienda USL\u2010IRCCS di Reggio Emilia  Reggio Emilia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Braglia","sequence":"additional","affiliation":[{"name":"Clinical Trials Center, Azienda USL\u2010IRCCS di Reggio Emilia  Reggio Emilia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Fabiano","sequence":"additional","affiliation":[{"name":"Hematology Unit, Azienda USL\u2010IRCCS di Reggio Emilia  Reggio Emilia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana Maria Rita","family":"Alfano","sequence":"additional","affiliation":[{"name":"Hematology Unit, Azienda USL\u2010IRCCS di Reggio Emilia  Reggio Emilia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monia","family":"Rinaldini","sequence":"additional","affiliation":[{"name":"Medical Genetics Unit, Azienda USL\u2010IRCCS di Reggio Emilia  Reggio Emilia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Bizzarri","sequence":"additional","affiliation":[{"name":"Medical Genetics Unit, Azienda USL\u2010IRCCS di Reggio Emilia  Reggio Emilia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Cattani","sequence":"additional","affiliation":[{"name":"Medical Genetics Unit, Azienda USL\u2010IRCCS di Reggio Emilia  Reggio Emilia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Marinelli","sequence":"additional","affiliation":[{"name":"Medical Genetics Unit, Azienda USL\u2010IRCCS di Reggio Emilia  Reggio Emilia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Gamberi","sequence":"additional","affiliation":[{"name":"Hematology Unit, Azienda USL\u2010IRCCS di Reggio Emilia  Reggio Emilia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,4,19]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13020256"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2021.1983427"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102016\u201001\u2010631200"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02614"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO\u201024\u201001893"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.11.014"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571\u2010025\u201001041\u2010x"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2025.0023"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(20)30756\u20107"},{"key":"e_1_2_12_11_1","unstructured":"mSMART \u201cTreatment Guidelines: Multiple Myeloma \u201d(2024) mSMART https:\/\/www.msmart.org\/mm\u2010treatment\u2010guidelines."},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277\u2010025\u201006212\u20105"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.4338"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.47"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408\u2010025\u201001253\u20105"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2024.2357382"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(14)70442\u20105"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(16)30206\u20106"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(19)31240\u20101"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(24)00282\u20101"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714678"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(19)32956\u20103"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607751"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00940"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606038"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02734"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(20)30734\u20100"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010026"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(21)00128\u20105"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352\u20103026(23)00218\u20101"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312054"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817249"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375\u2010024\u201002505\u20102"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102022\u2010163494"},{"key":"e_1_2_12_35_1","doi-asserted-by":"crossref","unstructured":"P.Moreau T.Facon S. Z.Usmani et\u00a0al. \u201cDaratumumab Plus Lenalidomide and Dexamethasone (D\u2010Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant\u2010Ineligible Patients With Newly Diagnosed Multiple Myeloma (NDMM): Clinical Assessment of Key Subgroups of the Phase 3 MAIA Study \u201dPoster presented at: 64th American Society of Hematology (ASH) Annual Meeting and Exposition New Orleans LA\/Virtual meeting2022.","DOI":"10.1182\/blood-2022-163494"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352\u20103026(23)00217\u2010X"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408\u2010024\u201001088\u20106"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01935"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352\u20103026(23)00236\u20103"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010024\u201003485\u20107"},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.7529"},{"key":"e_1_2_12_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16292"},{"key":"e_1_2_12_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277\u2010022\u201004978\u20106"},{"key":"e_1_2_12_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277\u2010023\u201005188\u20104"},{"key":"e_1_2_12_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2024.11.002"},{"key":"e_1_2_12_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.14413"},{"key":"e_1_2_12_47_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277\u2010021\u201004704\u20108"},{"key":"e_1_2_12_48_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0258487"},{"key":"e_1_2_12_49_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102022\u2010169533"},{"key":"e_1_2_12_50_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17081261"},{"key":"e_1_2_12_51_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277\u2010024\u201005835\u20104"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.70198","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ejh.70198","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.70198","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T16:31:43Z","timestamp":1783009903000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.70198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,19]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1111\/ejh.70198"],"URL":"https:\/\/doi.org\/10.1111\/ejh.70198","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,19]]},"assertion":[{"value":"2025-12-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}